China SXT Pharmaceuticals, Inc. (SXTC)
Total Valuation
SXTC has a market cap or net worth of $41.47 million. The enterprise value is $27.86 million.
| Market Cap | 41.47M |
| Enterprise Value | 27.86M |
Important Dates
The last earnings date was Monday, August 19, 2019, before market open.
| Earnings Date | Aug 19, 2019 |
| Ex-Dividend Date | n/a |
Share Statistics
SXTC has 10.45 million shares outstanding.
| Shares Outstanding | 10.45M |
| Owned by Insiders (%) | 19.63% |
| Owned by Institutions (%) | 3.40% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,233.50 |
| Forward PS | n/a |
| PB Ratio | 2.82 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 828.64 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.35, with a Debt / Equity ratio of 0.26.
| Current Ratio | 1.35 |
| Quick Ratio | 1.29 |
| Debt / Equity | 0.26 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11.45 |
Financial Efficiency
Return on equity (ROE) is -38.10% and return on invested capital (ROIC) is -24.15%.
| Return on Equity (ROE) | -38.10% |
| Return on Assets (ROA) | -18.80% |
| Return on Capital (ROIC) | -24.15% |
| Revenue Per Employee | $431 |
| Profits Per Employee | -$76,087 |
| Employee Count | 78 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -69.23% in the last 52 weeks. The beta is 0.82, so SXTC's price volatility has been lower than the market average.
| Beta (1Y) | 0.82 |
| 52-Week Price Change | -69.23% |
| 50-Day Moving Average | 2.17 |
| 200-Day Moving Average | 4.23 |
| Relative Strength Index (RSI) | 79.72 |
| Average Volume (30 Days) | 164,509 |
Short Selling Information
| Short Interest | 19,907 |
| Short Previous Month | 30,034 |
| Short % of Shares Out | 4.66% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.11 |
Income Statement
In the last 12 months, SXTC had revenue of $33,621 and -$5.93 million in losses. Loss per share was -$22.23.
| Revenue | 33,621 |
| Gross Profit | 1.58M |
| Operating Income | -4.45M |
| Pretax Income | -5.93M |
| Net Income | -5.93M |
| EBITDA | -5.13M |
| EBIT | -5.46M |
| Loss Per Share | -$22.23 |
Balance Sheet
The company has $17.37 million in cash and $3.76 million in debt, giving a net cash position of $13.61 million or $1.30 per share.
| Cash & Cash Equivalents | 17.37M |
| Total Debt | 3.76M |
| Net Cash | 13.61M |
| Net Cash Per Share | $1.30 |
| Equity / Book Value | 14.69M |
| Book Value Per Share | 1.41 |
| Working Capital | 5.02M |
Cash Flow
In the last 12 months, operating cash flow was -$80,757 and capital expenditures -$70,684, giving a free cash flow of -$151,441.
| Operating Cash Flow | -80,757 |
| Capital Expenditures | -70,684 |
| Free Cash Flow | -151,441 |
| FCF Per Share | -$0.57 |
Margins
Gross margin is 4,696.56%, with operating and profit margins of -13,249.91% and -17,651.98%.
| Gross Margin | 4,696.56% |
| Operating Margin | -13,249.91% |
| Pretax Margin | -17,651.98% |
| Profit Margin | -17,651.98% |
| EBITDA Margin | -15,272.60% |
| EBIT Margin | -16,233.89% |
| FCF Margin | -450.44% |
Dividends & Yields
SXTC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Earnings Yield | -14.31% |
| FCF Yield | -0.37% |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -827.57% |
| Shareholder Yield | -827.57% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on October 5, 2023. It was a reverse split with a ratio of 1:25.
| Last Split Date | Oct 5, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
SXTC has an Altman Z-Score of 0.25 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.25 |
| Piotroski F-Score | 3 |